 BEIJING, March 29, 2021 PRNewswire -- China Biologic Products Holdings, Inc. NASDAQ: CBPO, China Biologic or the Company, a leading fully integrated plasma-based biopharmaceutical company in China, today announced its financial results for the fourth quarter and fiscal year of 2020. Fourth Quarter 2020 Financial Highlights Total sales in the fourth quarter of 2020 increased by 9.7 in USD terms and 3.2 in RMB terms to 112.1 million from 102.2 million in the same quarter of 2019. 